千金藥業(600479.SH)前董事因未披露買賣8900股獲警示函
格隆匯12月9日丨千金藥業(600479.SH)公佈,近日,中國證券監督管理委員會湖南監管局對公司前董事羅勇下發了《關於對羅勇採取出具警示函措施的決定》,羅勇擔任公司董事期間,於2018年4月27日買入千金藥業股票8900股,又於2018年5月2日賣出千金藥業股票8900股。
上述行為違反了《中華人民共和國證券法》第四十七條的規定。鑑於買賣股票涉及的金額較小,所得收益已主動上繳給千金藥業,並於2019年3月2日辭去公司董事職務,違法行為輕微並已糾正,沒有造成嚴重危害後果。根據《行政處罰法》第二十七條第二款規定,依法不予行政處罰。為加強警示教育,採取出具警示函的行政監管措施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.